Influenza prevention and treatment by passive immunization

• Authors: Barbara Kalenik , Róża Sawicka , Anna Góra-Sochacka , Agnieszka Sirko
• Languages of publication: EN

Abstracts

EN

Passive immunity is defined as a particular antigen resistance provided by external antibodies. It can be either naturally or artificially acquired. Natural passive immunization occurs during pregnancy and breast-feeding in mammals and during hatching in birds. Maternal antibodies are passed through the placenta and milk in mammals and through the egg yolk in birds. Artificial passive immunity is acquired by injection of either serum from immunized (or infected) individuals or antibody preparations. Many independent research groups worked on selection, verification and detailed characterization of polyclonal and monoclonal antibodies against the influenza virus. Numerous antibody preparations were tested in a variety of in vitro and in vivo experiments for their efficacy to neutralize the virus. Here, we describe types of antibodies tested in such experiments and their viral targets, review approaches resulting in identification of broadly neutralizing antibodies and discuss methods used to demonstrate their protective effects. Finally, we shortly discuss the phenomenon of maternal antibody transfer as a way of effective care for young individuals and as an interfering factor in early vaccination.

Keywords

EN

antibody; clinical trials; hemagglutinin; influenza; neutralization; passive immunity

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2014
• Volume: 61
• Issue: 3
• Pages: 573-587

Dates

published

2014

received

2014-07-18

revised

2014-09-01

accepted

2014-09-01

(unknown)

2014-09-12

Contributors

author

Barbara Kalenik

• Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

author

Róża Sawicka

• Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

author

Anna Góra-Sochacka

• Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

author

Agnieszka Sirko

• Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

References

• Babickova J, Tothova L, Boor P, Celec P (2013) In vivo phage display - a discovery tool in molecular biomedicine. Biotechnol Adv 31: 1247-1259.
• Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D (2013) Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol 31: 647-652.
• Beerli RR, Bauer M, Schmitz N, Buser RB, Gwerder M, Muntwiler S, Renner WA, Saudan P, Bachmann MF (2009) Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J 6: 224.
• Benjamin E, Wang W, McAuliffe JM, Palmer-Hill FJ, Kallewaard NL, Chen Z, Suzich JA, Blair WS, Jin H, Zhu Q (2014) A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. J Virology 88: 6743-6750.
• Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vazquez M (2010) Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis 51: 1355-1361.
• Bouvier NM, Lowen AC (2010) Animal Models for Influenza Virus Pathogenesis and Transmission. Viruses 2: 1530-1563.
• Brandenburg B, Koudstaal W, Goudsmit J, Klaren V, Tang C, Bujny MV, Korse HJ, Kwaks T, Otterstrom JJ, Juraszek J, van Oijen AM, Vogels R, Friesen RH (2013) Mechanisms of hemagglutinin targeted influenza virus neutralization. PloS one 8: e80034.
• Brekke OH, Loset GA (2003) New technologies in therapeutic antibody development. Curr Opin Pharmacol 3: 544-550.
• Brydak LB, Nitsch-Osuch A (2014) Vaccination against influenza in pregnant women Acta Biochim Polon 61: 589-591.
• Bugli F, Cacaci M, Martini C, Torelli R, Posteraro B, Sanguinetti M, Paroni Sterbini F (2013) Human monoclonal antibody-based therapy in the treatment of invasive candidiasis. Clin Develop Immunol 2013: 403121.
• Chen J, Zhang F, Fang F, Chang H, Chen Z (2007) Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody. BMC Infectious Dis 7: 118.
• Clementi N, Criscuolo E, Castelli M, Clementi M (2012) Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. The New Microbiol 35: 399-406.
• Clementi N, De Marco D, Mancini N, Solforosi L, Moreno GJ, Gubareva LV, Mishin V, Di Pietro A, Vicenzi E, Siccardi AG, Clementi M, Burioni R (2011) A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PloS One 6: e28001.
• Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
• De Marco D, Clementi N, Mancini N, Solforosi L, Moreno GJ, Sun X, Tumpey TM, Gubareva LV, Mishin V, Clementi M, Burioni R (2012) A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PLoS One 7: e34415.
• Defang GN, Martin NJ, Burgess TH, Millar EV, Pecenka LA, Danko JR, Arnold JC, Kochel TJ, Luke TC (2012) Comparative analysis of hemagglutination inhibition titers generated using temporally matched serum and plasma samples. PloS One 7: e48229.
• Desai RG, Creger WP (1963) Maternofetal passage of leukocytes and platelets in man. Blood 21: 665-673.
• DiLillo DJ, Tan GS, Palese P, Ravetch JV (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 20: 143-151.
• Doyle TM, Hashem AM, Li C, Van Domselaar G, Larocque L, Wang J, Smith D, Cyr T, Farnsworth A, He R, Hurt AC, Brown EG, Li X (2013) Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res 100: 567-574.
• Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin O, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH (2012) Highly conserved protective epitopes on influenza B viruses. Science 337: 1343-1348.
• Du A, Daidoji T, Koma T, Ibrahim MS, Nakamura S, de Silva UC, Ueda M, Yang CS, Yasunaga T, Ikuta K, Nakaya T (2009) Detection of circulating Asian H5N1 viruses by a newly established monoclonal antibody. Biochem Biophys Res Commun 378: 197-202.
• Edwards MJ, Dimmock NJ (2000) Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition. Virology 278: 423-435.
• Eick AA, Uyeki TM, Klimov A, Hall H, Reid R, Santosham M, O'Brien KL (2011) Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatrics Adolescent Med 165: 104-111.
• Eikmans M, van Halteren AG, van Besien K, van Rood JJ, Drabbels JJ, Claas FH (2014) Naturally acquired microchimerism: Implications for transplantation outcome and novel methodologies for detection. Chimerism 5 (Epub ahead of print).
• Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333: 843-850.
• Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, Lee JH, Dillon MA, O'Neil RE, Faynboym AM, Horowitz M, Horowitz L, Ward AB, Palese P, Webby R, Lerner RA, Bhatt RR, Wilson IA (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489: 526-532.
• Fang Y, Banner D, Kelvin AA, Huang SS, Paige CJ, Corfe SA, Kane KP, Bleackley RC, Rowe T, Leon AJ, Kelvin DJ (2012) Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism. Journal of virology 86: 2229-2238.
• Fu TM, Freed DC, Horton MS, Fan J, Citron MP, Joyce JG, Garsky VM, Casimiro DR, Zhao Q, Shiver JW, Liang X (2009) Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 385: 218-226.
• Fujimoto Y, Ozaki K, Maeda M, Nishijima K, Takakuwa H, Otsuki K, Kida H, Ono E (2013) Resistance to influenza A virus infection in transformed cell lines expressing an anti-PB2 monoclonal antibody. Veterinary J 198: 487-493.
• Gamblin SJ, Skehel JJ (2010) Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285: 28403-28409.
• Grandea AG 3rd, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui PY, Mitcham JL, Cieplak W, Stewart SM, Grantham ML, Pekosz A, Kiso M, Shinya K, Hatta M, Kawaoka Y, Moyle M (2010) Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci USA 107: 12658-12663.
• Hairul Bahara NH, Tye GJ, Choong YS, Ong EB, Ismail A, Lim TS (2013) Phage display antibodies for diagnostic applications. Biologicals: Journal of the International Association of Biological Standardization 41: 209-216.
• Hassiotou F, Beltran A, Chetwynd E, Stuebe AM, Twigger AJ, Metzger P, Trengove N, Lai CT, Filgueira L, Blancafort P, Hartmann PE (2012) Breastmilk is a novel source of stem cells with multilineage differentiation potential. Stem Cells 30: 2164-2174.
• Heng BC, Cao T (2005) Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody). Medical Hypotheses 64: 1105-1108.
• Herbreteau CH, Jacquot F, Rith S, Vacher L, Nguyen L, Carbonnelle C, Lotteau V, Jolivet M, Raoul H, Buchy P, Saluzzo JF (2014) Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice. Immunotherapy 6: 699-708.
• Howard MK, Sabarth N, Savidis-Dacho H, Portsmouth D, Kistner O, Kreil TR, Ehrlich HJ, Barrett PN (2011) H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PloS one 6: e23791.
• Hu H, Voss J, Zhang G, Buchy P, Zuo T, Wang L, Wang F, Zhou F, Wang G, Tsai C, Calder L, Gamblin SJ, Zhang L, Deubel V, Zhou B, Skehel JJ, Zhou P (2012) A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J Virol 86: 2978-2989.
• Huang L, Su X, Federoff HJ (2013) Single-chain fragment variable passive immunotherapies for neurodegenerative diseases. Int J Mol Sci 14: 19109-19127.
• Hui DS, Lee N, Chan PK (2013) Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res 98: 410-416.
• Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY (2011) Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52: 447-456.
• Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, Liu R, Lai KY, Lau CC, Liu SH, Chan KH, Lin CK, Yuen KY (2013) Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144: 464-473.
• Hwang SD, Shin JS, Ku KB, Kim HS, Cho SW, Seo SH (2010) Protection of pregnant mice, fetuses and neonates from lethality of H5N1 influenza viruses by maternal vaccination. Vaccine 28: 2957-2964.
• Iwatsuki-Horimoto K, Horimoto T, Noda T, Kiso M, Maeda J, Watanabe S, Muramoto Y, Fujii K, Kawaoka Y (2006) The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J Virol 80: 5233-5240.
• Jakeman KJ, Smith H, Sweet C (1989) Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins. J Gen Virol 70: 1523-1531.
• Jeanty C, Derderian SC, Mackenzie TC (2014) Maternal-fetal cellular trafficking: clinical implications and consequences. Curr Opin Pediatrics 26: 377-382.
• Joob B, Wiwanitkit V (2013) Hyperimmune IV immunoglobulin treatment of 2009 influenza A(H1N1). Chest 144: 712.
• Kaku Y, Noguchi A, Okutani A, Inoue S, Tanabayashi K, Yamamoto Y, Hotta A, Suzuki M, Sugiura N, Yamada A (2012) Altered specificity of single-chain antibody fragments bound to pandemic H1N1-2009 influenza virus after conversion of the phage-bound to the soluble form. BMC Res Notes 5: 483.
• Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, Wall KM, Perry KJ, Faynboym A, Ilhan M, Horowitz M, Horowitz L, Palese P, Bhatt RR, Lerner RA (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 105: 5986-5991.
• Keller MA, Stiehm ER (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13: 602-614.
• Khurana S, Suguitan AL Jr, Rivera Y, Simmons CP, Lanzavecchia A, Sallusto F, Manischewitz J, King LR, Subbarao K, Golding H (2009) Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Medicine 6: e1000049.
• Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE Jr (2011) A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 85: 10905-10908.
• Krause JC, Tumpey TM, Huffman CJ, McGraw PA, Pearce MB, Tsibane T, Hai R, Basler CF, Crowe JE, Jr. (2010) Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol 84: 3127-3130.
• Kubota-Koketsu R, Yunoki M, Okuno Y, Ikuta K (2012) Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010. Biologics 6: 245-247.
• Laursen NS, Wilson IA (2013) Broadly neutralizing antibodies against influenza viruses. Antiviral Res 98: 476-483.
• Lerner EA (1981) How to make a hybridoma. Yale J Biol Med 54: 387-402.
• Lim AP, Wong SK, Chan AH, Chan CE, Ooi EE, Hanson BJ (2008) Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1. Virol J 5: 80.
• Liu W, Zou P, Chen YH (2004) Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 93: 131-136.
• Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Int Med 145: 599-609.
• Maas R, Rosema S, van Zoelen D, Venema S (2011) Maternal immunity against avian influenza H5N1 in chickens: limited protection and interference with vaccine efficacy. Avian Pathology: Journal W.V.P.A 40: 87-92.
• Mancini N, Solforosi L, Clementi N, De Marco D, Clementi M, Burioni R (2011) A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral Res 92: 15-26.
• Mozdzanowska K, Maiese K, Furchner M, Gerhard W (1999) Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254: 138-146.
• Mukhtar MM, Li S, Li W, Wan T, Mu Y, Wei W, Kang L, Rasool ST, Xiao Y, Zhu Y, Wu J (2009) Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription. Int J Biochem Cell Biol 41: 554-560.
• Oh HL, Akerstrom S, Shen S, Bereczky S, Karlberg H, Klingstrom J, Lal SK, Mirazimi A, Tan YJ (2010) An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J Virol 84: 8275-8286.
• Okada J, Ohshima N, Kubota-Koketsu R, Ota S, Takase W, Azuma M, Iba Y, Nakagawa N, Yoshikawa T, Nakajima Y, Ishikawa T, Asano Y, Okuno Y, Kurosawa Y (2010) Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified into three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003. Virology 397: 322-330.
• Pitaksajjakul P, Lekcharoensuk P, Upragarin N, Barbas CF 3rd, Ibrahim MS, Ikuta K, Ramasoota P (2010) Fab MAbs specific to HA of influenza virus with H5N1 neutralizing activity selected from immunized chicken phage library. Biochem Biophys Res Commun 395: 496-501.
• Poungpair O, Pootong A, Maneewatch S, Srimanote P, Tongtawe P, Songserm T, Tapchaisri P, Chaicumpa W (2010) A human single chain transbody specific to matrix protein (M1) interferes with the replication of influenza A virus. Bioconjug Chem 21: 1134-1141.
• Prabakaran M, Prabhu N, He F, Hongliang Q, Ho HT, Qiang J, Meng T, Goutama M, Kwang J (2009) Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One 4: e5672.
• Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, Goutama M, Kwang J (2009) Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol 83: 2553-2562.
• Rinaldi C, Penhale WJ, Stumbles PA, Tay G, Berry CM (2014) Modulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis. PLoS One 9: e89674.
• Roncada P, Stipetic LH, Bonizzi L, Burchmore RJ, Kennedy MW (2013) Proteomics as a tool to explore human milk in health and disease. J Proteomics 88: 47-57.
• Schirrmann T, Meyer T, Schutte M, Frenzel A, Hust M (2011) Phage display for the generation of antibodies for proteome research, diagnostics and therapy. Molecules 16: 412-426.
• Shahzad MI, Naeem K, Mukhtar M, Khanum A (2008) Passive immunization against highly pathogenic Avian Influenza Virus (AIV) strain H7N3 with antiserum generated from viral polypeptides protect poultry birds from lethal viral infection. Virol J 5: 144.
• Shoji Y, Chichester JA, Palmer GA, Farrance CE, Stevens R, Stewart M, Goldschmidt L, Deyde V, Gubareva L, Klimov A, Mett V, Yusibov V (2011) An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses. Human Vaccines 7 (Suppl): 199-204.
• Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha do Q, Farrar J, de Jong MD, Lanzavecchia A, Subbarao K (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Medicine 4: e178.
• Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
• Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA (2004) Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 101: 2536-2541.
• Sun L, Lu X, Li C, Wang M, Liu Q, Li Z, Hu X, Li J, Liu F, Li Q, Belser JA, Hancock K, Shu Y, Katz JM, Liang M, Li D (2009) Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PloS One 4: e5476.
• Thathaisong U, Maneewatch S, Kulkeaw K, Thueng-In K, Poungpair O, Srimanote P, Songserm T, Tongtawe P, Tapchaisri P, Chaicumpa W (2008) Human monoclonal single chain antibodies (HuScFv) that bind to the polymerase proteins of influenza A virus. Asian Pacific Journal of Allergy and Immunology/Launched by the Allergy and Immunology Society of Thailand 26: 23-35.
• Thomas PG, Keating R, Hulse-Post DJ, Doherty PC (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12: 48-54.
• Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+memory B cells. PLoS One 3: e3942.
• Tillib SV, Ivanova TI, Vasilev LA, Rutovskaya MV, Saakyan SA, Gribova IY, Tutykhina IL, Sedova ES, Lysenko AA, Shmarov MM, Logunov DY, Naroditsky BS, Gintsburg AL (2013) Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). Antiviral Res 97: 245-254.
• Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, Yang H, Chen X, Recuenco S, Gomez J, Chen LM, Johnson A, Tao Y, Dreyfus C, Yu W, McBride R, Carney PJ, Gilbert AT, Chang J, Guo Z, Davis CT, Paulson JC, Stevens J, Rupprecht CE, Holmes EC, Wilson IA, Donis RO (2013) New world bats harbor diverse influenza A viruses. PLoS Pathogens 9: e1003657.
• Tutykhina IL, Sedova ES, Gribova IY, Ivanova TI, Vasilev LA, Rutovskaya MV, Lysenko AA, Shmarov MM, Logunov DY, Naroditsky BS, Tillib SV, Gintsburg AL (2013) Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Res 97: 318-328.
• Velkov T, Ong C, Baker MA, Kim H, Li J, Nation RL, Huang JX, Cooper MA, Rockman S (2013) The antigenic architecture of the hemagglutinin of influenza H5N1 viruses. Mol Immunol 56: 705-719.
• Virdi V, Depicker A (2013) Role of plant expression systems in antibody production for passive immunization. Int J Dev Biol 57: 587-593.
• Wallach MG, Webby RJ, Islam F, Walkden-Brown S, Emmoth E, Feinstein R, Gronvik KO (2011) Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice. Clin Vaccine Immunol: CVI 18: 1083-1090.
• Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L, Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC (2013) Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J Virol 87: 9290-9300.
• Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, Koriazova L, Madura L, Shapiro L, Matsumoto A, Yoshida H, Mikayama T, Kubo RT, Sarawar S, Cheroutre H, Kato S (2008) Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80: 168-177.
• Whaley KJ, Zeitlin L (2013) Antibody-based concepts for multipurpose prevention technologies. Antiviral Res 100 (Suppl): S48-S53.
• Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX, Harrison SC (2011) Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA 108: 14216-14221.
• WHO (2013) Laboratory Procedures. Serological detection of avian influenza A(H7N9) infections by microneutralization assay. available on line:
• Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181-193.
• Wu R, Li X, Leung HC, Cao Z, Qiu Z, Zhou Y, Zheng BJ, He Y (2014) A novel neutralizing antibody against diverse clades of H5N1 influenza virus and its mutants capable of airborne transmission. Antiviral Res 106: 13-23.
• Xu Y, Li X, Jin L, Zhen Y, Lu Y, Li S, You J, Wang L (2011) Application of chicken egg yolk immunoglobulins in the control of terrestrial and aquatic animal diseases: a review. Biotechnol Adv 29: 860-868.
• Yamazaki T, Nagashima M, Ninomiya D, Arai Y, Teshima Y, Fujimoto A, Ainai A, Hasegawa H, Chiba J (2011) Passive immune-prophylaxis against influenza virus infection by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from plasmids. Jap J Infect Dis 64: 40-49.
• Yang YE, Wen J, Zhao S, Zhang K, Zhou Y (2014) Prophylaxis and therapy of pandemic H1N1 virus infection using egg yolk antibody. J Virol Methods 206: 19-26.
• Yewdell JW, Frank E, Gerhard W (1981) Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol 126: 1814-1819.
• Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, Ito K, Takada A (2009) Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathogens 5: e1000350.
• Young KH (1998) Yeast two-hybrid: so many interactions, (in) so little time. Biol Reprod 58: 302-311.
• Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, Stevens J, Wilson IA, Aguilar PV, Altschuler EL, Basler CF, Crowe JE, Jr. (2008) Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455: 532-536.
• Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, Omer SB, Shahid NS, Breiman RF, Steinhoff MC (2008) Effectiveness of maternal influenza immunization in mothers and infants. New England J Med 359: 1555-1564.
• Zebedee SL, Lamb RA (1988) Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62: 2762-2772.
• Zhang F, Fang F, Chang H, Peng B, Wu J, Chen J, Wang H, Chen Z (2013) Comparison of protection against H5N1 influenza virus in mouse offspring provided by maternal vaccination with HA DNA and inactivated vaccine. Arch Virol 158: 1253-1265.
• Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. New England J Medi 357: 1450-1451.